Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma
Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM) Background: MM inevitably relapses and becomes refractory to treatment, representing a patient (pt) population with unmet needs. Teclistamab (JNJ-64007957) is a bispecific BCMA x CD3 […]
Read More